Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD

The inhaled long-acting muscarinic antagonist aclidinium bromide has been shown to significantly improve lung function parameters and symptom severity in patients with COPD in randomised placebo- and active-controlled clinical studies. To obtain a comprehensive view of the treatment effects, patient-reported outcomes were investigated in a real-life COPD population in routine clinical practice in Austria.

Source: Respiratory Medicine CME - February 17, 2015 Category: Respiratory Medicine Authors: Katharina Marth, Elisabeth Schuller, Wolfgang Pohl, On behalf of the A NEED team Source Type: research